Thermo Fisher posts 6.2% growth

Lab-tools earnings are starting to sketch a very specific picture. Thermo Fisher came in first with a solid-looking quarter on April 23, posting 6% revenue growth to $11.01 billion and nudging up full-year guidance. But the more interesting part is what happened around it — Avantor was basically flat a week later, while Waters posted a much faster quarter after folding in a big biosciences acquisition. Put that together and the market looks less like a broad rebound and more like a patchwork. ### What business are we even talking about? These are the companies that sell the picks and shovels of modern biology — instruments, reagents, diagnostics gear, bioprocessing equipment, and lab services. When pharma labs, hospitals, or chip fabs spend more, these vendors feel it. When customers freeze budgets, the pain shows up here fast. That is why their quarterly numbers are a useful read on the health of research and industrial demand more broadly. ### What did Thermo Fisher actually report? Thermo Fisher reported first-quarter revenue of $11.01 billion for the period ended March 28, 2026. GAAP EPS rose 11% to $4.43, adjusted EPS rose 6% to $5.44, and the company raised its 2026 outlook to $47.3 billion to $48.1 billion in revenue with adjusted EPS of $24.64 to $25.12. On the surface, that is a clean beat-and-raise quarter. ### Why does the 6% growth number need an asterisk? Because most of that growth was not pure underlying demand. Thermo Fisher said organic revenue was up just 1%. The rest came from acquisitions and currency. Clario, which Thermo Fisher closed in late March, added about $30 million in first-quarter revenue, and favorable FX helped too. Basically, the headline was strong, but the core volume story was still modest. ### How did Avantor look by comparison? Avantor’s quarter on April 29 was much less flashy. Net sales were $1.58 billion, down 1% reported and flat organically, though adjusted EPS of $0.23 beat the company’s own prior guidance range. Management kept talking about its “Revival” plan — fixing execution, supply chain, and commercial basics after a rough 2025. So this was more stabilization than acceleration. ### Why did Waters look so much stronger? Waters reported first-quarter revenue of $1.267 billion on May 5, and the key reason was obvious — this was the first quarter including revenue from BD’s Biosciences and Diagnostic Solutions businesses, acquired on February 9. Organic revenue still rose a strong 13% as reported, but the reported total also included $six. ### So is the whole sector recovering? Not evenly. Thermo Fisher showed steady execution but only light organic growth. Avantor showed that broad lab supply demand is still sluggish. Waters showed that exposure to the right end markets — especially biosciences and diagnostics — can produce a very different quarter. That is the big read-through. Investors are no longer rewarding “science tools” as one bucket. They are rewarding where each company sits inside the bucket. ### What does that mean for the next few quarters? It means earnings season is going to be about mix, not just scale. Companies tied to bioprocessing, diagnostics, and specialized workflows have a clearer path to growth. Companies exposed to routine lab spending still need customer budgets to thaw. Thermo Fisher’s quarter matters because it looked strong enough to calm nerves, but not strong enough to prove a broad-based rebound has arrived. ### Bottom line? Thermo Fisher’s 6% growth was real, but it was not a clean signal that the whole tools market is back. The clearer signal is segmentation — some niches are moving again, and some are still stuck.